Healthcare
Pulmonx Corporation(LUNG)
Live Price
Offline$1.28
+2.40% today
1Y Change
-51.74%
Window
Jun 26, 2025 โ Jun 17, 2026
- Market Cap
- $60.00M
- Revenue Growth
- +8.0%
- EPS Growth
- +7.6%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 26, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pulmonx Corporation (LUNG) is a Healthcare stock with a market cap of $60.00M and listed on NASDAQ. The stock last traded around $1.28 and down 51.7% across the available one-year price window (Jun 26, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +8.0%, EPS growth of +7.6%, a dividend yield of 0.0%. What stands out right now is revenue +8.0%, EPS +7.6%, free cash flow +0.3% with operating margin -58.8% and ROIC -50.8%. Valuation is more restrained than many high-expectation growth names at price/sales 0.6. Stock Foundry combines LUNG price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+8.0% vs +7.6% peer median
Operating Margin
Below sector median
-58.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +8.0% and EPS at +7.6%, with operating margin around -58.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.9% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 29, 2026 | โ | +6.7% | +7.5% | +40.0% |
2026 Mar 4, 2026 | +35.9% | +11.8% | +24.7% | -11.1% |
2025 Nov 12, 2025 | +15.0% | -18.9% | -29.6% | +28.1% |
Benchmark Edge
LUNG vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LUNG
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LUNG Max Drawdown
-69.05%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LUNG and SPY.
Company Overview
Pulmonx Corporation
NASDAQ Global Select
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
- Leadership
- Glendon E. French
- IPO Date
- Oct 1, 2020
- Employees
- 291
- Street Address
- 700 Chesapeake Drive
- Mailing
- Redwood City, CA, 94063
- Region
- Redwood City, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 364 0400
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.6
- Price/Book
- 1.2
Growth
- Revenue
- +8.0%
- EPS
- +7.6%
- Free Cash Flow
- +0.3%
Profitability
- Gross Margin
- 75.5%
- Operating Margin
- -58.8%
- Net Margin
- -60.1%
- ROE
- -92.9%
- ROIC
- -50.8%
Balance Sheet
- Debt/Equity
- 1.23
- Current Ratio
- 4.91
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.